PuSH - Publication Server of Helmholtz Zentrum München: Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: A secondary analysis of a randomized clinical trial.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Budau, L.* ; Wilhelm, C.* ; Moll, R.* ; Jäkel, J.* ; Hirt, C.* ; Dölken, G.* ; Maschmeyer, G.* ; Neubauer, E.* ; Strauch, K. ; Burchert, A.* ; Herold, M.* ; Neubauer, A.*

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: A secondary analysis of a randomized clinical trial.

J. Cancer Res. Clin. Oncol. 145, 2149-2156 (2019)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

BackgroundFirst-line rituximab therapy together with chemotherapy is the standard care for patients with advanced follicular B-cell lymphoma, as rituximab together with chemotherapy prolongs progression-free and overall survival (Herold et al. 2007; Marcus et al. 2005). However, as not all patient subgroups benefit from combined immuno-chemotherapy, we asked whether the microenvironment may predict benefit from rituximab-based therapy.DesignTo address this question, we performed a retrospective immunohistochemical analysis on pathological specimens of 18 patients recruited into a randomized clinical trial, where patients with advanced follicular lymphoma were randomized into either chemotherapy or immuno-chemotherapy with rituximab (Herold et al. 2007).ResultsWe show here that rituximab exerts beneficial effects, especially in the subgroup of follicular lymphoma patients with low intrafollicular CD3, CD5, CD8, and ZAP70 and high CD56 and CD68 expression.ConclusionRituximab may overcome immune-dormancy in follicular lymphoma in cases with lower intrafollicular T-cell numbers and higher CD56 and CD68 cell counts. As this was a retrospective analysis on a small subgroup of patients, these data need to be corroborated in larger clinical trials.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Follicular Lymphoma ; Microenvironment ; Rituximab ; T Cells ; Nk Cells ; Macrophages; Tumor Microenvironment; Retrospective Analysis; 1st-line Mitoxantrone; Prognostic Value; Gene-expression; Survival; Transformation; Cyclophosphamide; Immunotherapy; Prednisolone

ISSN (print) / ISBN 0171-5216

e-ISSN 1432-1335

Journal Journal of Cancer Research and Clinical Oncology

Quellenangaben Volume: 145, Issue: 8, Pages: 2149-2156

Publisher Springer

Publishing Place 233 Spring St, New York, Ny 10013 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Genetic Epidemiology (IGE)